SOLICITATION NOTICE
B -- Etiologic Factors for Prostate Cancer Progression in the Prostate, Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial
- Notice Date
- 9/9/2011
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-110185-TG
- Archive Date
- 10/5/2011
- Point of Contact
- Terry Galloway, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
gallowaytl@mail.nih.gov, cr214i@nih.gov
(gallowaytl@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6074, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Center Division of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB), plans to procure on a sole source basis services for review of Etiologic Factors for Prostate Cancer Progression in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial with Regents of the University of Minnesota, Office of Sponsored Projects Administration, 450 McNamara Alumni Center, 200 Oak Street SE, Minneapolis, MN 55455-2070. This acquisition will be processed in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1 (b)(1). The North American Industry Classification System code is 541990 and the business size standard is $7 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of performance shall be for twelve months from date of award. The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, sponsored by the National Cancer Institute, is a multicenter randomized trial that is evaluating the effectiveness of prostate, lung, colorectal, and ovarian cancer screening modalities on disease-specific mortality. To date, over 7500 men have been diagnosed with early stage prostate cancer while participating in the PLCO trial. On average, between 15-35% of men with early stage disease will experience a biochemical recurrence (elevation in PSA) after receiving initial treatment for their prostate cancer. The additional data collection requested will develop a PLCO resource that can facilitate the identification of the most relevant etiologic factors associated with prostate cancer recurrence and progression. The purpose of this procurement is to obtain additional clinical and treatment information from men diagnosed with clinically localized prostate cancer in PLCO. Information will be collected by telephone interview with the male subject, or a proxy if necessary, and be validated with medical records. Regents of the University of Minnesota is one of the 10 screening centers participating in the PLCO trial. It has received Internal Review Board (IRB) approval to contact and actively follow PLCO participants in their area over the course of the PLCO trial. No other entity has obtained consent to contact these individuals at this time and to reconsent these individuals with an outside entity after 17 years of continued follow-up within the existing infrastructure of PLCO would result in a nontrivial loss of participants. Regents of the University of Minnesota will contact 866 PLCO subjects and obtain 87 medical record abstractions from their unique population. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on September 20, 2011. No electronic capability statements will be accepted (i.e. email or fax). An original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and may be faxed (301) 402-4513 or emailed to Terry Galloway, Contract Specialist at gallowaytl@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-110185-TG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-110185-TG/listing.html)
- Record
- SN02570347-W 20110911/110910000807-790f072b414e243c8baaf0fabfa954b5 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |